Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
- Posted on October 30, 2025
- By CNBC
- 1 Views
Shares of breast cancer therapy developer Olema Pharmaceutical could more than double from here
The clinical-stage biopharma stock has rallied more than 70% over the past three months on the back of promising clinical data for its lead drug, Palazestrant.
